TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $168 | -36.4% | 18,804 | +9.6% | 0.00% | -50.0% |
| Q2 2023 | $264 | -37.9% | 17,163 | -9.2% | 0.00% | -33.3% |
| Q1 2023 | $425 | +22.8% | 18,901 | +15.0% | 0.00% | 0.0% |
| Q4 2022 | $346 | -99.9% | 16,440 | -7.6% | 0.00% | 0.0% |
| Q3 2022 | $438,000 | +103.7% | 17,793 | +100.8% | 0.00% | +200.0% |
| Q2 2022 | $215,000 | -26.4% | 8,859 | -21.8% | 0.00% | 0.0% |
| Q1 2022 | $292,000 | -9.3% | 11,332 | +9.3% | 0.00% | 0.0% |
| Q4 2021 | $322,000 | +59.4% | 10,367 | +24.5% | 0.00% | 0.0% |
| Q3 2021 | $202,000 | – | 8,330 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |